Evidence map›Paper›PMID 35211754›Full record

ArticleInternational journal of oncology2022

Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma.

Marc A Schneider, Sarah Richtmann, Anna R Gründing, Sabine Wrenger, Tobias Welte, Michael Meister, Mark Kriegsmann, Hauke Winter, Thomas Muley, Sabina Janciauskiene

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Marc A SchneiderTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany.
Sarah RichtmannTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany.
Anna R GründingDepartment of Respiratory Medicine, Hannover Medical School, D-30625 Hannover, Germany.
Sabine WrengerDepartment of Respiratory Medicine, Hannover Medical School, D-30625 Hannover, Germany.
Tobias WelteDepartment of Respiratory Medicine, Hannover Medical School, D-30625 Hannover, Germany.
Michael MeisterTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany.
Mark KriegsmannTranslational Research Center Heidelberg (TLRC), Member of The German Center for Lung Research (DZL), D-69120 Heidelberg, Germany.
Hauke WinterTranslational Research Center Heidelberg (TLRC), Member of The German Center for Lung Research (DZL), D-69120 Heidelberg, Germany.
Thomas MuleyTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, D-69126 Heidelberg, Germany.
Sabina JanciauskieneDepartment of Respiratory Medicine, Hannover Medical School, D-30625 Hannover, Germany.
Medizinische Hochschule Hannover · DEUniversity Hospital Heidelberg · DEGerman Center for Lung Research · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transmembrane serine protease 2 (TMPRSS2) has been intensively investigated during the current Sars‑CoV‑2 pandemic as a virus activating protease. Furthermore,

Indexed as

PrognosisAdenocarcinoma of LungBiomarkers, TumorCell Line, TumorHumansSerine EndopeptidasesBiomarkers, TumorSerine EndopeptidasesTMPRSS2 protein, humanalpha1‑antitrypsinlung cancerprognostic factorSERPINA1TMPRSS2

Identifiers

PMID35211754
PMCPMC8878627
OpenAlexW4213285578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.